(0.09%) 5 474.01 points
(0.13%) 39 164 points
(0.39%) 17 786 points
(0.05%) $80.87
(-3.66%) $2.66
(-0.77%) $2 312.80
(0.18%) $28.92
(3.67%) $1 022.60
(0.28%) $0.936
(0.70%) $10.68
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases...
Stats | |
---|---|
今日成交量 | 306 910 |
平均成交量 | 193 348 |
市值 | 54.39M |
EPS | $-0.460 ( Q1 | 2024-05-09 ) |
下一个收益日期 | ( $-0.360 ) 2024-08-08 |
Last Dividend | $0.361 ( 2023-03-08 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.170 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00700 (0.54%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-17 | Morris Richard Steven | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Klichinsky Michael | Buy | 85 000 | Stock Option (Right to Buy) |
2024-06-17 | Kelly Steven | Buy | 125 000 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 38 700 | Stock Option (Right to Buy) |
2024-04-01 | Hohneker John | Buy | 0 |
INSIDER POWER |
---|
100.00 |
Last 7 transactions |
Buy: 1 112 700 | Sell: 0 |
音量 相关性
Carisma Therapeutics, 相关性 - 货币/商品
Carisma Therapeutics, 财务报表
Annual | 2023 |
营收: | $14.92M |
毛利润: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2023 |
营收: | $14.92M |
毛利润: | $6.65M (44.60 %) |
EPS: | $-2.59 |
FY | 2022 |
营收: | $9.83M |
毛利润: | $3.74M (38.07 %) |
EPS: | $-575.42 |
Financial Reports:
No articles found.
Carisma Therapeutics, Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.361 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.361 | 2023-03-08 |
Last Dividend | $0.361 | 2023-03-08 |
Next Dividend | $0 | N/A |
Payout Date | 2023-03-08 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.361 | -- |
Avg. Dividend % Per Year | 0.94% | -- |
Score | 0.39 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.361 | 2.82% |
2024 | $0 | 0.00% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
08 Mar 2023 | $0.361 | 03 Feb 2023 | 07 Mar 2023 | 08 Mar 2023 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -5.39 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -1.101 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -2.16 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 4.64 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 4.42 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 4.30 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.102 | -1.500 | 8.31 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -103.61 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.968 | -1.935 | [0 - 20] |
debtEquityRatioTTM | 0.688 | -1.500 | 7.25 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.656 | 1.000 | 2.40 | 2.40 | [0.2 - 0.8] |
operatingProfitMarginTTM | -5.66 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -10.44 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.204 | 0.800 | -1.972 | -1.577 | [0.5 - 2] |
Total Score | -1.801 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.580 | 1.000 | -0.160 | 0 | [1 - 100] |
returnOnEquityTTM | -2.16 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.935 | 2.00 | -0.645 | -1.935 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.911 | 2.00 | -0.637 | -1.274 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0261 | 1.500 | -3.51 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -5.19 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -2.80 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Carisma Therapeutics,
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。